Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2023 (1 December 2022 – 30 November 2023) and its outlook for 2024.
– First efficacy data from the clinical trial with HDP-101 in multiple myeloma
– Expansion of the ADC technology platform to include further payloads
– New Management Board team
– Successful financing activities; sales revenue and other income above plan
– Conference call to be held on 25 March 2024 at 03:00 pm CET / 10:00 am EDT